Department of Infectious Disease, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
JAMA Netw Open. 2024 Nov 4;7(11):e2445525. doi: 10.1001/jamanetworkopen.2024.45525.
The burden of liver cancer varies worldwide. An upward trend in both hepatocellular carcinoma (HCC) incidence and mortality in the past 2 decades has been observed.
To assess observed HCC-related age-standardized mortality rates (ASMRs) in the US for 2006 to 2022 and provide ASMR projections through 2040.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the National Vital Statistics System, which is accessible through the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research website. Data on deaths attributed to HCC (from January 1, 2006, to December 31, 2022) were obtained for adults 25 years or older and were stratified by liver disease etiology, age, sex, and race and ethnicity. Etiologies included alcohol-associated liver disease (ALD), hepatitis B virus (HBV), hepatitis C virus (HCV), and metabolic dysfunction-associated steatotic liver disease (MASLD).
The main outcomes were (1) observed ASMRs of HCC per 100 000 persons using Joinpoint regression (National Cancer Institute) to assess trends during 2006 to 2022 and (2) ASMRs projected for 2023 to 2040 using Prophet and AutoARIMA modeling.
This study included 188 280 HCC-related deaths from 2006 to 2022. Most deaths occurred among males (77.4%). The annual percentage change was 4.1% (95% CI, 2.2% to 7.7%) for 2006 to 2009 and decreased to 1.8% (95% CI, 0.7% to 2.0%) for 2009 to 2022, with an overall observed ASMR of 5.03 per 100 000 persons in 2022 and a projected ASMR of 6.39 per 100 000 persons by 2040, with consistent trends for both sexes. By etiology, ASMRs decreased for HCV- and HBV-related mortality but increased for ALD- and MASLD-related mortality. In 2022, MASLD surpassed HBV as the third-leading cause of HCC-related death and was projected to overtake HCV in 2032 as the second-leading cause; ALD was projected to be the leading cause of HCC-related death in 2026. In 2022, the ASMR was higher among individuals aged 65 years or older compared with those aged 25 to 64 years (18.37 vs 1.79 per 100 000 persons). The American Indian or Alaska Native population had the largest increase in projected ASMR by 2040 (14.71 per 100 000 persons) compared with the Asian population (3.03 per 100 000 persons).
In this cross-sectional study, ASMRs for ALD- and MASLD-related HCC death increased rapidly from 2006 to 2022; ALD-related HCC was projected to be the leading cause by 2026, with MASLD as the second-leading cause by 2032. These findings may serve as a reference for public health decision-making and timely identification of groups at high risk of HCC death.
肝癌的负担在全球范围内有所不同。过去 20 年来,肝癌(HCC)的发病率和死亡率呈上升趋势。
评估美国 2006 年至 2022 年观察到的与 HCC 相关的年龄标准化死亡率(ASMR),并提供到 2040 年的 ASMR 预测。
设计、地点和参与者:这项横断面研究使用了美国国家生命统计系统的数据,该数据可通过疾病控制和预防中心的广泛在线数据用于流行病学研究网站获取。数据包括 25 岁及以上成年人归因于 HCC 的死亡(从 2006 年 1 月 1 日至 2022 年 12 月 31 日),并按肝脏疾病病因、年龄、性别和种族和民族进行分层。病因包括酒精相关性肝病(ALD)、乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和代谢功能障碍相关性脂肪性肝病(MASLD)。
主要结果是(1)使用 Joinpoint 回归(美国国家癌症研究所)评估 2006 年至 2022 年期间的趋势,观察每 10 万人中与 HCC 相关的 ASMR;(2)使用 Prophet 和 AutoARIMA 模型预测 2023 年至 2040 年的 ASMR。
这项研究包括 2006 年至 2022 年期间与 HCC 相关的 188280 例死亡。大多数死亡发生在男性(77.4%)中。2006 年至 2009 年的年百分比变化为 4.1%(95%CI,2.2%至 7.7%),2009 年至 2022 年下降至 1.8%(95%CI,0.7%至 2.0%),2022 年的观察性 ASMR 为每 10 万人 5.03 人,预计到 2040 年将达到每 10 万人 6.39 人,两种性别均呈持续趋势。按病因分类,HCV 和 HBV 相关死亡率下降,但 ALD 和 MASLD 相关死亡率上升。2022 年,MASLD 超过 HBV 成为 HCC 相关死亡的第三大病因,并预计在 2032 年超过 HCV 成为第二大病因;ALD 预计将成为 2026 年 HCC 相关死亡的主要病因。2022 年,65 岁及以上人群的 ASMR 高于 25 至 64 岁人群(每 10 万人中 18.37 人比 1.79 人)。与亚洲人口(每 10 万人 3.03 人)相比,美国印第安人或阿拉斯加原住民人口预计到 2040 年的 ASMR 增幅最大(每 10 万人 14.71 人)。
在这项横断面研究中,ALD 和 MASLD 相关 HCC 死亡的 ASMR 从 2006 年至 2022 年迅速增加;预计到 2026 年,ALD 相关 HCC 将成为主要病因,到 2032 年,MASLD 将成为第二大病因。这些发现可能为公共卫生决策提供参考,并及时识别 HCC 死亡风险较高的人群。